Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study examined current literature and recommendations for preventing and treating skin lesions induced by chemotherapy, highlighting common dermatological issues such as discoloration, pruritus, and alopecia, and noting that specific treatments can alleviate these problems to improve patients' skin integrity, self-esteem, and quality of life.

This study found that in keratin 14-targeted transgenic mice, BMP antagonism via noggin led to the development of hair follicle tumors, mediated through alterations in Wnt and Shh signaling pathways.

This study identified NM_026333 as a potential anti-aging gene that, when induced, may alleviate proton-induced aging symptoms in CF6-overexpressing and high salt-fed mice.

This review discusses the progress and challenges of targeted protein degradation therapies, highlighting the increasing number of degraders in cancer clinical trials and the limited diversity in targeted proteins, primarily focusing on those employing CRL4^CRBN as the E3 ligase.

This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.

In this study, a superoxide dismutase gel prevented hair graying in mice exposed to photosensitization, suggesting that antioxidants can protect against oxidative damage involved in hair aging.

This study reports that targeted anticancer therapies frequently cause skin-related side effects, which may impact patient adherence and quality of life, but these effects are positively correlated with treatment response.

This review outlines various non-rash skin toxicities associated with novel targeted anticancer therapies and provides guidelines for their early diagnosis and management, but reports no new clinical results.

In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.

This review discusses the mechanisms associated with protoporphyrin IX in living cells and reports no clinical results; the authors emphasize its potential in cancer diagnosis and the risks of toxicity.

In this study, a biocompatible zinc oxide nanocomposite loaded with the anticancer drug 9-Br-Nos demonstrated effective drug delivery and cytotoxicity against lung cancer cells in vitro, while also proving non-toxic to healthy cells, suggesting its potential for targeted lung cancer treatment.

This review highlights REV7's crucial roles in maintaining genome stability, its implication in several cancers, and its association with poor prognoses and treatment resistance, while also noting that REV7 suppression may improve chemotherapy sensitivity.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

In this study, the multifunctional Hair BB Cream containing botanical extracts and other ingredients improved hair combability, increased shine and strength, and provided UV protection, highlighting its potential as an effective hair care product.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

This study found that selective inactivation of ribonucleotide excision repair in mouse epidermis led to spontaneous DNA damage, skin inflammation, and the development of squamous cell carcinoma, suggesting potential implications for cancer development in humans.

This study found that overexpression of the enzyme ornithine decarboxylase in transgenic mice led to UVB-induced skin tumors, but this was prevented by the ODC inhibitor α-difluoromethylornithine.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

This study demonstrated that a light-activated RNAi approach using hollow gold nanoshells effectively targets human prostate cancer cells with reduced off-target toxicity and material use compared to standard methods.

This study found that the CDK4/6 inhibitor palbociclib may protect human hair follicles from the damaging effects of taxane chemotherapy by inducing G1 arrest in stem/progenitor cells.

This study found that red ginseng oil promoted hair growth and protected against UVC-induced skin damage in mouse models.

In this study, researchers found that male and female APCHi mice exposed to ionizing radiation showed near-normal lipid and metabolite levels, suggesting activated protein C may offer some protective effects against radiation-induced damage affecting organ systems.

This pilot study suggests that topical melatonin may protect hair follicle stem cells from paclitaxel-induced damage, potentially preventing chemotherapy-induced alopecia and enhancing the effects of scalp cooling caps.

This study developed an inexpensive method to provide initial data on both the photostability and toxicity of pure active principles and their photodegradation products.

In this study, preconditioning hair follicle-derived stem cells with valproic acid and/or rapamycin was shown to protect against damage caused by oxygen glucose and serum deprivation, potentially enhancing stem cell therapy efficacy for ischemic stroke by improving cell adaptation to oxidative stress.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This review discusses emerging cancer treatment methods focusing on cellular mechanisms unique to cancer cells and concludes no new clinical results.

This article provides a narrative on managing dermatologic side effects from cancer therapies and suggests strategies that oncologists could adopt, but it reports no new clinical findings.